美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

iShares Neuroscience and Healthcare ETF

36.37

+0.34660.96%

成交量：214

成交額：7,784.98

市值：727.40萬

市盈率：- -

高：36.37

開：36.37

低：36.37

收：36.02

52周最高：43.01

52周最低：25.42

股本：20.00萬

流通股本：20.00萬

量比：0.99

換手率：0.11%

股息：0.32

股息率：0.88%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

成都腦機接口產業有望再添技術成果

Scholar Rock重磅宣佈：FDA批准Isembyld™（Apitegromab-Mstn）上市，成為首個且唯一針對脊髓性肌萎縮症（SMA）兒童與成人患者的肌肉靶向療法

Scholar Rock Holding Corporation——Isembyld美國商業上市正式啓動，產品即將發貨

美國食品藥品監督管理局（FDA）批准了Scholar Rock公司的一款治療肌肉無力症的藥物

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

美國研究綜述-Adobe、Chewy、Mosaic

湖北：圍繞光通信、高端芯片、北斗高精度定位等開展集中攻關推進人工智能、具身智能、量子科技、腦機接口、6G等前沿方向原始創新

北京：加速量子科技、腦機接口、第六代移動通信等領域新產品創制

翔宇醫療與浙江省中醫院共建腦機接口康復診療中心

格式塔創始人彭雷：三到五年內，腦機接口本質上是嚴肅的醫療器械

腦機接口公司術理創新4日正式啓動科創板上市輔導。

Scholar Rock旗下Apitegromab獲FDA快速通道資格，面肩肱型肌營養不良症二期試驗啓動給藥

央視財經：百億級市場新「機」遇來了！腦機接口產業駛入快車道

美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極

深圳：擬統籌規劃腦解析與腦模擬重大科技設施

《深圳經濟特區促進腦機接口產業創新發展若干規定》公開徵求意見

機器如何讀懂人腦意圖？瓦博科技在腦機接口跑出新賽道

全球首例：眼球植入半侵入式視網膜腦機接口，患者重見光明

郭廣昌：復星在神經退行性疾病領域「全面佈局」，部分治療帕金森症和阿爾茲海默症的藥物「時間不會太長」

*ST明德(002932.SZ)：暫未直接開展腦機接口業務

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/IBRN/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":36.3701,"timestamp":1789654682031,"preClose":36.0235,"halted":0,"volume":214,"delay":0,"changeRate":0.009621497078296175,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"交易中","change":0.3466,"latestTime":"09-17 10:25:03 EDT","open":36.3701,"high":36.3701,"low":36.3701,"amount":7784.975460000001,"amplitude":0,"askPrice":36.72,"askSize":400,"bidPrice":36.47,"bidSize":400,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":36.0235,"sharesOutstanding":150000,"nav":36.206255,"aum":7241251,"dividendRate":0.008815,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":36.1985,"preClose":36.0235,"latestTime":"16:10 EDT","volume":6,"amount":216.274,"timestamp":1789589404213,"change":0.175,"changeRate":0.004858,"amplitude":0},"volumeRatio":0.989613,"impliedVol":0.2051,"impliedVolPercentile":0.9402},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.989613,"shares":200000,"dividePrice":0.3206,"high":36.3701,"amplitude":0,"preClose":36.0235,"low":36.3701,"week52Low":25.4196,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":36.3701,"eps":0,"divideRate":0.008815,"volume":214,"delay":0,"ttmEps":0,"open":36.3701,"prevYearClose":32.3193,"prevWeekClose":37.4262,"prevMonthClose":38.9601,"prevQuarterClose":38.8263,"fiveDayClose":37.33,"twentyDayClose":40.6657,"sixtyDayClose":36.8908},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667319366","title":"成都腦機接口產業有望再添技術成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2667319366","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667319366?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 10:02","pubTimestamp":1789351357,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198447746","title":"Scholar Rock重磅宣佈：FDA批准Isembyld™（Apitegromab-Mstn）上市，成為首個且唯一針對脊髓性肌萎縮症（SMA）兒童與成人患者的肌肉靶向療法","url":"https://stock-news.laohu8.com/highlight/detail?id=1198447746","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198447746?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 06:26","pubTimestamp":1789165582,"startTime":"0","endTime":"0","summary":"Scholar Rock公司今日正式宣告，美国食品药品监督管理局已批准其创新药物Isembyld上市。这一里程碑式的决定，标志着该药物成为全球首个且唯一的肌肉靶向治疗手段，专门面向脊髓性肌萎缩症患者群体——无论是儿童还是成人，均适用此疗法。与现有治疗方案相比，Isembyld独辟蹊径，直接作用于肌肉组织本身，而非仅仅靶向神经系统通路。Scholar Rock方面表示，此次FDA的审批通过，凝聚了公司多年来的科研心血与临床试验成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","THNR","BK4139","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146877625","title":"Scholar Rock Holding Corporation——Isembyld美國商業上市正式啓動，產品即將發貨","url":"https://stock-news.laohu8.com/highlight/detail?id=1146877625","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146877625?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 06:26","pubTimestamp":1789165570,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding Corporation宣布，其旗下产品Isembyld在美国的商业上市进程已正式拉开帷幕。目前，该产品已处于可发运状态，预计将在未来数日内陆续送达相关渠道。这一里程碑式的进展，标志着公司在商业化道路上迈出了坚实的一步。据悉，产品现已准备就绪，即将进入物流配送环节，以满足市场预期需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","SRRK","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666257258","title":"美國食品藥品監督管理局（FDA）批准了Scholar Rock公司的一款治療肌肉無力症的藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666257258","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666257258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 05:25","pubTimestamp":1789161915,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）批准了Scholar Rock公司的一款治疗肌肉无力症的药物路透9月11日-美国食品和药物管理局（FDA）周五批准了Scholar Rock公司开发的SRRK.O疗法，用于治疗一种会导致肌肉无力的罕见遗传性疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4T4531I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","BK4588","IBRN","IE00B19Z9P08.USD","BK4533","LU0320765992.SGD","LU0234570918.USD","BMED","PBE","THNR","SRRK","LU0109394709.USD","BK4532","BK4139","IE00B894F039.SGD","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GNOM","SYNB","LU2322448791.USD","TMED","LFSC","HELX","LU1992135399.USD","PBE","BK4585","FTXH","BBH","CANC","LU2272731600.USD","LU2272731865.HKD","RSPH","PSCH","IBB","IDNA","IEIH","MRNY","XBIX","BK4588","FBT","BME","RXL","AZNH","LU2322448957.HKD","PJP","XPH","IEHS","LU2272731782.SGD","WDNA","IBRN","BIOY","LU2473716301.USD","IYH","MEDI","IE00B5TLWC47.USD","BBP","MRNX","LU1992135472.HKD","BIB","PPH","PBPH","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666974541","title":"美國研究綜述-Adobe、Chewy、Mosaic","url":"https://stock-news.laohu8.com/highlight/detail?id=2666974541","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666974541?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:10","pubTimestamp":1789110636,"startTime":"0","endTime":"0","summary":"美国研究综述-Adobe、Chewy、Mosaic路透9月11日-周五，华尔街证券分析师修订了对多家在美国上市的公司的评级和目标股价。要点* Adobe IncADBE.O：杰富瑞将目标价从285美元下调至275美元* Chewy IncCHWY.N：摩根大通将评级从“超配”下调至“中性”* 摩萨克公司MOS.N：Keybanc首次覆盖，给予“与行业持平”评级* PaychexPAYX.O：道明考恩将目标价从98美元上调至117美元* ValvolineVVV.N：RBC将目标价从46美元上调至49美元以下是路透周五报导的关于美国公司研究动向的摘要。股票按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4T4530JW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1037948541.HKD","FTAG","LU0323591593.USD","LU1267930813.SGD","IE00BMPRXN33.USD","LU1430597077.USD","EYES","LU0511384066.AUD","LU2250418816.HKD","SG9999003800.SGD","LU0154236417.USD","LU0289961442.SGD","LU1989772840.SGD","IE00B42XCP33.USD","LU0061475181.USD","BK4538","LU1093756168.USD","PYZ","LU0158827948.USD","BK4554","PLTZ","SG9999001440.SGD","BK4023","LU0612318971.USD","ADBG","TRUM","LU1201861249.SGD","IE00BLSP4452.SGD","IE00B3S45H60.SGD","LU2746668461.USD","LU0472753341.HKD","LU1046421795.USD","BK4543","LU0070302665.USD","WLK","LU1935043536.SGD","LU0320765059.SGD","LU0289739343.SGD","LU2108987350.USD","BK4550","BK4504","LU1861558580.USD","SG9999015986.USD","LU1093756325.SGD","PLTI","LU1691799644.USD","LU0300736062.USD","SG9999015978.USD","IE00BZ9MQY76.HKD","SPLTRmain","LU1670628061.USD","BK4093","PAWZ","LU0792757196.USD","BK4561","LU0476273544.USD","LU1815336760.USD","LU0320765489.SGD","LU2380233275.USD","TDIV","LU2458330169.SGD","CHWY","SGXZ81514606.USD","LU1935042215.USD","LU1720051108.HKD","LU1935042991.SGD","LU2896262040.SGD","LU0385154629.USD","IE00BDGV0183.EUR","IE0002270589.USD","BK4533","LU2095319765.USD","LU0056508442.USD","CE","BK4122","CTVA","LU1169589451.USD","APD","LU0256863811.USD","LU0985320562.USD","IE00B775SV38.USD","LU1823568750.SGD","IE00BLSP4239.USD","PLYY","AXTA","LU0553294199.USD","PLTD","ORCS","BK4197","LU0345774631.USD","ATO","LU0345780950.USD","IE00BQXX3C00.GBP","LU1935042488.USD","LU1852331112.SGD","LU0612318385.USD","IE0009356076.USD","LU0661504455.SGD","LU1506573853.SGD","ORCL","LU1894683348.USD","LU2543165471.USD","LU0738911758.USD","IE00B3PB1722.GBP","SORCLmain","LU1720051017.SGD","LU2089284900.SGD","IBRN","IE00B19Z9505.USD","LU2125154778.USD","LU0868494617.USD","LU0742534661.SGD","LU2087625088.SGD","LU1366333091.USD","BK4534","RPM","LU2237438978.USD","LU1435385759.SGD","BK4581","LU0082616367.USD","LU2860962120.EUR","LU1712237335.SGD","LU1261432733.SGD","LU0708995401.HKD","BK4109","LU0965509101.SGD","LU1235294995.USD","IE00BQXX3D17.EUR","LU0949170772.SGD","LU1623119135.USD","LU1037948897.HKD","LU1429558221.USD","LU2362540622.SGD","LU1934455863.HKD","BK4567","LU1267930730.SGD","LU0417517546.SGD","LU0957808578.USD","LU2210149790.SGD","LU0068578508.USD","LU0545039389.USD","IE00B5TLWC47.USD","BK4613","LU0157215616.USD","BK4101","LU1778281490.HKD","BK4527","LU0965508806.USD","IE00BMPRXR70.SGD","PTIR","BK4130","LU1941712348.USD","BK4211","SG9999015952.SGD","LU0251142724.SGD","PPG","LU0289960550.SGD","LU1119994496.HKD","SHW","BK4548","LU2362541273.HKD","IE00B7SZLL34.SGD","IE00BMPRXQ63.HKD","SHLD","CF","LU0861579265.USD","LU0048573561.USD","LU1674673428.USD","PLOO","IE00B19Z3B42.SGD","LU0208291251.USD","LU0300736492.USD","LU1642822529.SGD","LU0889566641.SGD","LU0868494708.USD","SG9999001424.SGD","PLTW","LU0081259029.USD","BK4559","IE00B3T34201.USD","LU0061474960.USD","HUN","LU0210536198.USD","MOS","LU2326559502.SGD","LU0109391861.USD","LU1633808545.USD","LU1989764748.USD","LU0477156953.USD","IE00BVYPNW00.USD","LU1989772923.USD","LU0314106906.USD","PAYX","IE00BQXX3F31.USD","LU2236285917.USD","OGIG","LU0130517989.USD","PLTU","LU0234572021.USD","BK4090","BK4566","LU0345781412.USD","SGXZ51526630.SGD","LU0234570918.USD","LU0719512351.SGD","LU1035773651.USD","PLT","PLTL","IE00BFMHRM44.USD","BK4528","GUNZ","PLTR","LU1366192091.USD","VEGI","BK4592","BK4178","LU2237957902.USD","IE00B19Z9P08.USD","LU0444973449.USD","ORCU","LU0054578231.USD","LU1934455194.USD","LU0630314457.HKD","SG9999015945.SGD","LU1935043023.USD","LU1069347547.HKD","LU0106261372.USD","BK4516","BK4106","LU0471298777.SGD","IE00BBT3K403.USD","LU0965509283.SGD","OLN","LU1670627923.USD","LU0345774391.USD","LU2023251221.USD","VVV","PBJ","BK4139","LU0433182093.SGD","LU2360106780.USD","LU1861559042.SGD","LU0957791311.USD","IE00B19Z3581.USD","BK4214","IE00BYQQ9H92.USD","LU1803068979.SGD","IE00BFXG0V08.USD","LU0648001328.SGD","LU2210150020.SGD","LU1084165304.USD","ONB","BK4597","LU0654597011.USD","BK4585","ORCX","LU0348723411.USD","LU2125154935.USD","LU1003077747.HKD","LU2746668974.SGD","LU0965509010.AUD","EMN","LU1989764664.SGD","BK4535","LU0170899867.USD","LU0353189680.USD","IE00B19Z9Z06.USD","LU1815333072.USD","BK4545","LU2458330243.SGD","LU1674673691.USD","KROP","FMC","LU0557290698.USD","LU1934455277.USD","PSCM","LU2357305700.SGD","BK4098","IE0004445239.USD","SG9999002521.SGD","LU1548497426.USD","LU2360032135.SGD","LU0889565833.HKD","LU1169590202.USD","IE00B894F039.SGD","LU2362541513.USD","BK4200","LU0980610538.SGD","IE00B5949003.HKD","ADBU","DNTH","LU0006306889.USD","RH","LU0342679015.USD","PLTA","LU0130102774.USD","LU0985489474.SGD","LU1074936037.SGD","IBAT","LU2089283258.USD","LU0069063385.USD","LU1941712264.USD","IE00BGHQF631.EUR","PLTY","LU1489326972.SGD","AIPI","LU0942090050.USD","ORCZ","LU0109392836.USD","LU0444971666.USD","LU0314104364.USD","LU1894683264.USD","IGV","IE00BVYPNV92.GBP","BK4547","LU0878866978.SGD","BK4097","LU0672654240.SGD","SG9999011175.SGD","ORAC","LU2237957811.SGD","LU0353189763.USD","LU2317271919.USD","IFF","SGXZ99366536.SGD","BK4588","LU2211817866.USD","LU0057025933.USD","LU0198837287.USD","LU0251131958.USD","LU0006061336.USD","ADBE","IE00BN8TJ469.HKD","LU0175139822.USD","SG9999000418.SGD","LU2054465674.USD","PLTG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666156558","title":"湖北：圍繞光通信、高端芯片、北斗高精度定位等開展集中攻關 推進人工智能、具身智能、量子科技、腦機接口、6G等前沿方向原始創新","url":"https://stock-news.laohu8.com/highlight/detail?id=2666156558","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666156558?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:43","pubTimestamp":1789026224,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["OGIG","159813","USD","LYTE","NBDS","AIBU","QTUP","161631","QSWN","SIXG","MVPS","SOXS","SSG","AGIX","CPNQ","FTXL","AIQU","PBOT","KOMP","NEWZ","SMHX","QUA","IBRN","SOXL","AQGX","TECY","MNTL","XSD","CHAT","FOTO","ARTY","WDRN","CHPS","SOXY","TEKX","SOXQ","LUMA","VUSE","SMH","PSI","WPAI","TARK","DQJN","LCLG","QID","QTOC","SOXX","AIFD","FWD","CHPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666651583","title":"北京：加速量子科技、腦機接口、第六代移動通信等領域新產品創制","url":"https://stock-news.laohu8.com/highlight/detail?id=2666651583","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666651583?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 15:46","pubTimestamp":1788939970,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["QBY","IBRN","QBTX","QTUP","QUA","QBTZ","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665632021","title":"翔宇醫療與浙江省中醫院共建腦機接口康復診療中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2665632021","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665632021?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:17","pubTimestamp":1788869871,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665350040","title":"格式塔創始人彭雷：三到五年內，腦機接口本質上是嚴肅的醫療器械","url":"https://stock-news.laohu8.com/highlight/detail?id=2665350040","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665350040?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 14:01","pubTimestamp":1788588060,"startTime":"0","endTime":"0","summary":"格式塔创始人、CEO彭雷表示，脑机接口赛道要解决的核心问题就一个：持续提高对脑内读写的分辨率。在他看来，至少在看得见的三到五年内，脑机接口本质上还是严肃的医疗器械，它的创新落地，付费方一定是医疗体系与患者。他指出，如何依托我国特色的医疗保障体系，让前沿的脑机接口应用纳入医保，惠及更多患者、解决实际病痛，这就是付费层面需要思考的问题。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-09-05/doc-iniquccw0443893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","MEDX","IBRN","09996","LGHT","HART","BK1100","IEIH","GDOC","MNTL","RSPH","AGNG","159883","MDEV","BK1574","PTH","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665206350","title":"腦機接口公司術理創新4日正式啓動科創板上市輔導。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665206350","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665206350?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 13:26","pubTimestamp":1788585983,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNTL","IBRN","KSTR","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135653463","title":"Scholar Rock旗下Apitegromab獲FDA快速通道資格，面肩肱型肌營養不良症二期試驗啓動給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1135653463","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135653463?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:01","pubTimestamp":1788350501,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding Corp宣布，其针对面肩肱型肌营养不良症的在研药物Apitegromab已获得美国食品药品监督管理局的快速通道认定。与此同时，该药物的二期FORGE试验已正式启动受试者给药。这一里程碑式的进展标志着Scholar Rock在攻克这一罕见神经肌肉疾病方面迈出了关键一步。值得注意的是，FSHD是一种进行性加重的肌肉萎缩疾病，目前临床上缺乏有效的治疗手段。Apitegromab作为一种潜在的首创疗法，其研发进展备受业界关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","IBRN","SRRK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664893811","title":"央視財經：百億級市場新「機」遇來了！腦機接口產業駛入快車道","url":"https://stock-news.laohu8.com/highlight/detail?id=2664893811","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664893811?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 11:07","pubTimestamp":1788318460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664521258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["GNOM","PBE","BBH","BK4007","MRNY","IEHS","MRNX","PJP","FBT","RSPH","IBRN","IE0009355771.USD","SYNB","IDNA","MEDI","IBB","BIOY","TMED","FTXH","IEIH","LU0211331839.USD","LU2473716301.USD","IE00BFTCPJ56.SGD","HELX","IE00BJJMRZ35.SGD","SBIO","PSCH","BME","LU2272731600.USD","LFSC","BBP","LU2322448957.HKD","PBPH","PPH","IYH","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","CANC","BK4585","RXL","WDNA","XBIX","AZNH","BIB","LU0070302665.USD","NVS","MEDX","XPH","BK4588","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664824208","title":"深圳：擬統籌規劃腦解析與腦模擬重大科技設施","url":"https://stock-news.laohu8.com/highlight/detail?id=2664824208","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664824208?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 10:09","pubTimestamp":1788228547,"startTime":"0","endTime":"0","summary":"金吾财讯 | 《深圳经济特区促进脑机接口产业创新发展若干规定（征求意见稿）》公开征求意见。其中提到，市人民政府应当统筹规划脑解析与脑模拟重大科技设施、人脑组织资源库等科技与卫生基础设施，创新基础设施运营管理制度，完善基础设施开放共享、考核、激励等机制，为本市脑机接口产业发展提供公共服务。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MmE5ZmExMjY0NjZiOTEwNWRjYzNhYzE1NWFlMjE2MzgxNTIxMjk2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmE5ZmExMjY0NjZiOTEwNWRjYzNhYzE1NWFlMjE2MzgxNTIxMjk2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990185","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664088289","title":"《深圳經濟特區促進腦機接口產業創新發展若干規定》公開徵求意見","url":"https://stock-news.laohu8.com/highlight/detail?id=2664088289","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664088289?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 09:46","pubTimestamp":1788227219,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663076576","title":"機器如何讀懂人腦意圖？瓦博科技在腦機接口跑出新賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2663076576","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663076576?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 17:09","pubTimestamp":1788167340,"startTime":"0","endTime":"0","summary":"8月21日，脑机接口企业瓦博科技创始人张星智亮相新网银行“AI 构造力”直播栏目，与新华财经副总编辑陈冉就脑机接口行业的技术路线、商业化落地与行业伦理展开深度交流。同年3月，瓦博科技在成都注册成立，11月正式启动运营。瓦博科技落户成都并非偶然，张星智介绍到，高新区完备的科创扶持政策，叠加芯片、AI、生物医药产业集聚的产学研优势，十分适配脑机接口多学科交叉的赛道属性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/2026-08-31/doc-iniqfeap4611219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663301481","title":"全球首例：眼球植入半侵入式視網膜腦機接口，患者重見光明","url":"https://stock-news.laohu8.com/highlight/detail?id=2663301481","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663301481?lang=zh_tw&edition=fundamental","pubTime":"2026-08-29 10:17","pubTimestamp":1787969874,"startTime":"0","endTime":"0","summary":"IT之家 8 月 29 日消息，据武汉大学人民医院消息，因视网膜色素变性，60 岁的邱先生已彻底失明 4 年。官方表示，经公开文献检索，这是全球首例“高分辨率半侵入式视网膜脑机接口”临床应用获得安全有效成果的病例。视网膜色素变性等疾病会摧毁感光细胞以及部分节细胞，导致失明。过去国内外少量已报道的临床试验，多采用“全侵入”方案：打开眼球，将电极植入视网膜下方或上面，紧贴神经细胞刺激。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8vyowJ6pbJE","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662547620","title":"郭廣昌：復星在神經退行性疾病領域「全面佈局」，部分治療帕金森症和阿爾茲海默症的藥物「時間不會太長」","url":"https://stock-news.laohu8.com/highlight/detail?id=2662547620","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662547620?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 15:08","pubTimestamp":1787900894,"startTime":"0","endTime":"0","summary":"8月28日上午，复星国际召开2026年中期业绩发布会。在问答环节，复星国际董事长郭广昌重点谈到了公司在神经退行性疾病领域的布局，并直言这一市场空间巨大。郭广昌说，“说得直白一点，在座的如果活得足够长，1/3的人可能会有帕金森症，1/3的人可能会有阿尔茨海默症。”话音未落，现场便响起全场笑声。待气氛稍缓，郭广昌进一步披露公司的布局节奏：“而且都是在全面布局，而且我觉得有些药的话时间也不会太长了。”","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/08/28150858267468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00656","BK1230","IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662895580","title":"*ST明德(002932.SZ)：暫未直接開展腦機接口業務","url":"https://stock-news.laohu8.com/highlight/detail?id=2662895580","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662895580?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 22:57","pubTimestamp":1787842623,"startTime":"0","endTime":"0","summary":"格隆汇8月27日丨*ST明德(002932.SZ)在投资者互动平台表示，公司目前聚焦主业发展，暂未直接开展脑机接口业务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260827/32350751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IBRN","BK0239","MNTL","002932"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}